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Abstract: The high mortality rate of colorectal cancer (CRC) patients is directly associated with
metastatic dissemination. However, therapeutic options specifically for metastasis are still limited.
We previously identified Metastasis-Associated in Colon Cancer 1 (MACC1) as a major causal
metastasis-inducing gene. Numerous studies confirmed its value as a biomarker for metastasis
risk. We investigated the inhibitory impact of saffron on MACC1-induced cancer cell growth
and motility. Saffron crudes restricted the proliferation and migration of MACC1-expressing CRC
cells in a concentration- and MACC1-dependent manner. Saffron delays cell cycle progression at
G2/M-phase and does not induce apoptosis. Rescue experiments showed that these effects are
reversible. Analysis of active saffron compounds elucidated that crocin was the main compound that
reproduced total saffron crudes effects. We showed the interaction of MACC1 with the cancer stem cell
(CSC) marker DCLK1, which contributes to metastasis formation in different tumor entities. Saffron
extracts reduced DCLK1 with crocin being responsible for this reduction. Saffron’s anti-proliferative
and anti-migratory effects in MACC1-expressing cells are mediated by crocin through DCLK1
down-regulation. This research is the first identification of saffron-based compounds restricting
cancer cell proliferation and motility progression via the novel target MACC1.
Keywords: MACC1; colorectal cancer; metastasis; DCLK1; natural compounds
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1. Introduction
Colorectal cancer (CRC) is one of the most common cancers with metastasis formation responsible
for the majority of cancer related deaths [1,2]. It has been estimated that 90% of the CRC-specific
mortality were hinged on metastatic spread [3,4]. Despite treatment improvements, specific therapeutic
options are limited [2]. Colorectal cancer can be classified into consensus molecular subtypes
that are characterized by different molecular backgrounds including microsatellite stability, CpG
island methylation, mutational status, immune infiltration or signaling pathway activity (e.g.,
WNT/β-catenin) [5]. Profound knowledge of the molecular background of a tumor is needed
for successful treatment. Here, causal biomarkers, either as single genes or as member of a molecular
signature, driving tumor development, progression and metastasis formation, play an important role.
We identified Metastasis-Associated in Colon Cancer 1 (MACC1) as a causal metastasis-promoting
oncogene [6]. Elevated expression of this gene increases proliferation, migration, and invasiveness
of cancer cells. MACC1 promotes epithelial-mesenchymal transition (EMT), a process changing an
epithelial mostly low motile phenotype of cells towards a mesenchymal phenotype that is often linked
to an increased motility. Further, it increases angiogenesis and cancer stemness [6,7]. Clinically it was
shown that MACC1 expression promotes tumor progression and metastasis formation in more than
20 different solid tumor entities, including CRC [6,7]. High MACC1 expression is significantly linked
with decreased 5-year metastasis-free and overall survival, establishing its role as prognostic biomarker
for CRC [6,7]. The predictive value of MACC1 was shown e.g., for CRC and breast cancer [8,9]. These
studies highlight MACC1 as a target for cancer therapy.
Many research groups tried to improve existing treatment regimens and develop new drugs to
gain the desired remedial effects targeting malignant tumors. Insufficient outcomes and undesirable
side effects of these drugs urged researchers to study new approaches to achieve better treatment
outcomes. Many studies attempt to improve treatment by combining approved drugs with natural
compounds and to establish natural compound-based treatment regimens [10]. One of these promising
natural products is saffron (Crocus sativus). Therapeutic effects of saffron have been known since
ancient Egyptian time [11]. Saffron contains three major compounds responsible for its activity:
crocetin, safranal and crocin. The effects of saffron and its compounds have been investigated by
different research groups on several cancer entities [12,13]. These in vitro and in vivo studies revealed
anti-cancer effects via numerous mechanisms, including inhibition of DNA and RNA synthesis,
activation of STAT3, modulation of the immune system, suppression of telomerase activity, inhibition
of cell proliferation, modulation of metabolism, inhibition of cell cycle progression, and stimulation of
cell-to-cell gap junction [14–18]. Further, recent studies suggested possible anti-metastatic effects of
this natural product, including downregulation of matrix metalloproteinases (MMP) -2, -9, N-cadherin
expression reduction, and increase of E-cadherin [18–22].
Interestingly, besides other effects, saffron is also able to target cancer stem cells (CSC) via the
decrease of DCLK1 [23]. This population of cells is important for tumor (re)constitution and metastasis
formation [23].
The entire remedial effect of saffron and its compounds on tumor progression is not entirely
understood. In this study, we have investigated the impact of saffron crudes and selected saffron
compounds on MACC1-induced phenotypes. This is the first identification of saffron-based compounds
restricting cancer cell proliferation and motility via the novel target MACC1.
2. Methods
2.1. Cell Cultures
The cell lines SW480 and SW620 were obtained from the American Type Culture Collection
(Manassas, VA, USA). The cells were maintained in RPMI and DMEM (Invitrogen, Darmstadt,
Germany), respectively, supplemented with 10% (v/v) fetal calf serum (FCS) (Bio & Sell, Feucht,
Germany) at 37 ◦C with 5% CO2 in a humidified atmosphere. MACC1 was knocked-out in SW620
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by Crispr-Cas9: SW620/KO-MACC1 (control: SW620/Control). SW480/MACC1 cells were generated
by stable transfection of pcDNA3/MACC1 (controls: SW480/Control) [6] (Supplementary Figure S1).
HEK293T cells were cultured in DMEM/10% FCS. They were transduced with lentiviral DCLK1-GFP
and MACC1-RFP for the MACC1-DCLK1 interaction studies. Viruses were produced following
standard procedures using the plasmids psPAX2 (Addgene 12260), pMD2.G (Addgene 12259) and
pLenti vectors (Origene, Rockville, MD, USA) coding for GFP-tagged DCLK1 and RFP-tagged MACC1.
DCLK1 cDNA was a kind gift of C. W. Houchen (University of Oklahoma Health Sciences Center,
Oklahoma City, OK, USA). Positive cells were selected by FACS.
2.2. Preparation of Saffron Crudes, Compounds and DCLK1 Inhibitors
Experiments were performed with four different saffron crudes obtained from Gulf Pearls, SPRL
(Brussels, Belgium). For each experiment, fresh, sterile filtered saffron crudes (20 mg saffron crude
per ml water, 24 h shaking at room temperature) were prepared. Saffron crudes were used at final
concentrations of 1%, 2.5%, 5%, and 10% in complete growth medium. The difference between the
saffron samples is the concentration of the main compounds such as crocin and safranal. A final
compound concentration of 5 mM safranal, 5 mM crocin, and 5 µM crocetin has been used. DCLK1
inhibitor LRRK2-IN-1 has been used in concentrations between 0.78–25 µM.
2.3. RNA Extraction and Quantitative PCR
For the isolation of total RNA, the GeneMatrix Universal RNA purification Kit (EURx, Gdansk,
Poland) has been used according to the manufacturer’s instructions. Isolated RNA was eluted with
ultrapure water. RNA concentration was measured using a NanoDrop 2000 spectrophotometer (Peqlab,
Erlangen, Germany). For each sample, 50 ng total RNA has been reverse transcribed (Biozym, Hessisch
Oldendorf, Germany). The cDNAs were amplified using SYBR green chemistry (Biozym) according to
the manufacturer’s instructions using the LightCycler 480 (Roche Life Science, Mannheim, Germany)
with the primer sequences listed in Supplementary Table S1.
2.4. Co-Immunoprecipitation (Co-IP)
For Co-IP experiments, cells were scratched off with 500 µL Protease-Inhibitor containing IP-lysis
buffer (Roche Diagnostics, Risch, Switzerland). Cell lysates were centrifuged for 45 min at 14,000 rpm
at 4 ◦C. Proteins were pulled-down with 2 µg of the respective antibody overnight at 4 ◦C. Then
20 µL of G-agarose beads were added (Alpha Diagnostic International Inc., San Antonio, TX, USA)
and incubated for 4 h at 4 ◦C on a rotational shaker. After washing with lysis buffer, we eluted
the protein-complexes with DTT (AppliChem GmbH, Darmstadt, Germany) containing LDS-buffer
(Thermo Fisher Scientific, Waltham, MA, USA). Eventually, we spun at 2500 rpm for 5 min at 4 ◦C, and
20 µL of supernatant were transferred to the SDS page.
2.5. Protein Extraction and Western Blot
Saffron treated cells were lysed in RIPA buffer. Protein concentrations were quantified using
the Pierce BCA Protein Assay (Thermo Fischer Scientific) according to manufacturer’s instructions.
For MACC1 and DCLK1 30 µg, cleaved-caspase-3 and cleaved-PARP 60 µg protein lysates were
separated using 12% sodium dodecyl sulfate polyacrylamide gels. The proteins were transferred
to nitrocellulose membranes and incubated with the respective primary antibody followed by
HRP-labelled secondary antibodies. Bound antibodies were detected by incubating the membranes in a
chemiluminescent substrate (Advansta, San Jose, CA, USA). Protein bands were visualized by exposure
to SuperRX X-ray films (Fujifilm, Tokyo, Japan). β-actin and vinculin were used as loading controls.
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2.6. MTT Assay
Cells were treated with each of the four different saffron crudes for 24 h in 96-well plates. After
incubation with MTT (Thermo Fischer Scientific), cells were dissolved in DMSO, and absorbance was
measured with a multi-well plate reader (InfiniteM200 PRO, Tecan, Männedorf, Switzerland).
2.7. Flow Cytometry
To assess the cell cycle state, cells were treated with saffron extracts for 24 h, then harvested,
washed, and fixed with 66% ethanol for 2 h, at 4 ◦C. Next, cells were pelleted and resuspended in
200 µL RNAse and PI containing staining solution (20 min, 37 ◦C). The samples were analyzed using
LSR 2 flow cytometry (BD Bioscience, San Jose, CA, USA).
2.8. Migration Assay
For analyzing cell migration, the Boyden Chamber (Corning, New York, NY, USA) assay has
been used. Serum starved (6 h 0.5% FCS) cells were seeded in the upper chamber with 0.5% FCS;
10% FCS served as chemoattractant in the lower chamber. Saffron crudes and crocin were added to
both chambers. Migrated cells in the lower chamber were collected after 16 h and lysed with 20 µL of
CellTiter-Glo reagent (Promega, Madison, WI, USA). Luminescence was measured with a multi-well
plate reader (Infinite M200 PRO).
2.9. Live Cell Imaging
To detect the effect of saffron extracts on cell proliferation, IncuCyte ZOOM system
(Essen Bioscience, MI, USA) has been used. 1 × 104 cells/well were seeded in 96-well plates and treated
with different concentrations of saffron extracts or its compounds. Cell proliferation was assessed
every 2 h and analyzed using the integrated software.
To rescue saffron effects, cells were exposed to the saffron extracts for 24 h with subsequent
exposure to saffron-free culture medium.
2.10. Kinase Assay
For the kinase assay, DCLK1 was isolated from HEK293T cells after lentiviral transduction.
To isolate the protein, Nanotrap-based (ChromoTek, Martinsried, Germany) Co-IP for GFP was
performed following manufacturers recommendations. Cleared lysates of 107 cells were incubated
with Nanotrap-coupled beads for 1 h. After washing, the protein-loaded beads were directly used for
the kinase assay. Five-hundred nanograms of recombinant MACC1 (Origene, Rockville, MD, USA)
was incubated at 37 ◦C with 10 µg isolated DCLK1 in kinase buffer containing 0.3 µM γP32 ATP (Perkin
Elmer, Rodgau, Germany), 80 mM HEPES pH 7.5, 4 mM MgCl2, 4 mM MnCl2, 1.6 mM DTT, and
70 µg/mL PEG20,000 for 15, 30, 45, and 60 min. Samples were heat-inactivated and separated on 10%
polyacrylamide gels. The gels were dried on Whatman paper and bands were visualized with imaging
plates (BAS-IP MS 2340, Fujifilm, Japan) using an Amersham Typhoon FLA 7000 (GE Healthcare,
Freiburg, Germany).
2.11. FRET Measurement
For Förster resonance energy transfer (FRET) measurements, GFP- and RFP-tagged proteins were
overexpressed by lentiviral gene transfer in HEK293T cells. FACS-selected cells were seeded in rat
collagen (Santa Cruz, Dallas, TX, USA) coated chamber slides (Ibidi, Gräfelfing, Germany). After 24 h,
cells were fixed with 4% paraformaldehyde. FRET was analyzed at 63,000-fold magnification. Multiple
consecutive images for GFP- and RFP-positive cells were acquired using corresponding filter channels.
The pictures were analyzed in Image J (NIH, Bethesda, MD, USA) plugin ’FRETTY’. FRET efficacy has
been utilized between 0 and 1.
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2.12. Liquid Chromatography
Saffron samples have been characterized using HPLC and spectroscopy methods. Aqueous
extracts were prepared according to the ISO 3632 standard. Ultraviolet–visible spectral data in the
wavelength range of 200–600 nm and the intensities of the chromatographic peaks attributed to the
saffron compound crocin was recorded [24].
2.13. Statistical Analysis
All statistics were performed with GraphPad Prism version 6.0 (La Jolla, CA, USA). Comparisons
of two different groups were performed by Student’s t-test. For analysis of three or more groups,
one-way analysis of variance (ANOVA) with Dunnet´s post-hoc test was employed. p values smaller
than 0.05 were considered statistically significant (* = p < 0.05, ** = p < 0.01).
3. Results
3.1. Saffron Restricts Proliferation and Viability of CRC Cells with High MACC1 Expression
Initially, we evaluated the MACC1-dependent impact of four whole saffron crudes on cell
proliferation. Saffron samples (saffron 1–4) of different origin were used in this study to generalize
our findings for different saffron sources. We employed the MACC1 low-expressing CRC cell line
SW480 and clones thereof with stable ectopic MACC1 overexpression (SW480/MACC1). We treated
the cells with different saffron crudes for 72 h, and cell growth was monitored label-free using the
IncuCyte live cell imaging system every 2 h. High MACC1-expressing cells without any treatment
showed higher proliferation rates compared to the low MACC1-expressing cells. However, all MACC1
expressing cell lines treated with saffron crudes showed a decrease in proliferation. The reduction
differed between the saffron samples. Three days after treatment with 10% of each saffron crude,
MACC1-overexpressing SW480 cells showed a decrease in proliferation by 50%, 56%, 70%, and 59%,
with saffron samples 1, 2, 3, and 4, respectively. The cell line SW480/control is affected by saffron
treatment too, pointing to additional MACC1-independent effects. Lower concentration of saffron
treatment did not lead to the same effect (Figure 1A–D, Supplementary Figure S2). To further confirm
these results, similar experiments were performed in the SW620 cell line, which has an endogenously
high MACC1 level. In this cell line, MACC1 was knocked out by CRISPR/Cas9. Similar effects were
observed using saffron 1, 2, 3, and 4 crudes. They reduced the proliferation by 40%, 43%, 38%, and 47%,
respectively (Figure 1E–H). The effect of saffron on SW620/KO-MACC1 cells was not as prominent as
SW620/Control cells. This shows that the observed effect is mediated partially by MACC1, but points
to additional effects not mediated via this molecule. To further examine the effect of different saffron
crudes on the growth of the CRC cell lines, we treated the cells with different saffron crudes for 24 h and
assessed the amount of living cells by MTT. Saffron crudes reduced the viability of SW480/MACC1 cells
compared to solvent-treated cells in a concentration-dependent manner (Figure 1J). Each saffron sample
reduced proliferation and the viability of the CRC cells with high MACC1 expression. However, due to
different main compound ratios between different saffron samples, reduction rates differ. The strongest
effects were observed at the highest concentration of 10% with saffron sample 3. Cell viability of
SW480/MACC1 cells was reduced by 63% compared to control. A similar but less pronounced effect
was observed with saffron samples 1, 2, and 4. The reductions were 49%, 36% and 11%, respectively.
Using lower concentrations (5% saffron crude and below) of all tested saffron crudes showed no effects
on cell viability (Figure 1I) and proliferation (Supplementary Figure S2).
Cells 2020, 9, 1829 6 of 17
Cells 2020, 9, x 6 of 18 
 
 
Figure 1. Saffron crudes reduced the proliferation and viability of CRC cells in a MACC1-dependent 
manner. CRC cells were treated with four different saffron crudes. Every second hour the confluence 
of the cells was measured by a live cell imaging system. Each saffron crude reduced the proliferation 
of both SW480/MACC1 (A–D) and SW620/Control cells (E–H). Cell viability was further assessed 
using MTT assay, and correlatively to the previous results, each saffron crude decreased the cell 
viability in a concentration-dependent manner. Cells treated with 5% saffron did not show a reduced 
viability (I) whereas the 2-fold increased amount of saffron reduced the cell viability most 
pronounced for saffron 1, 2 and 3 (J). Data are represented as mean ± SEM (n ≥ 3). p values were 
calculated using one-way ANOVA, * p < 0.05. 
Figure 1. Saffron crudes reduced the proliferation and via ilit f CRC cells in a MACC1-dependent
manner. CRC cells were treated with four different saffron crudes. Every second hour the confluence of
the cells was measured by a live cell imaging system. Each saffron crude reduced the proliferation of
both SW480/MACC1 (A–D) and SW620/Control cells (E–H). Cell viability was further assessed using
MTT assay, and correlatively to the previous results, each saffron crude decreased the cell viability in
a concentration-dependent manner. Cells treated with 5% saffron did not show a reduced viability
(I) whereas the 2-fold increased amount of saffron reduced the cell viability most pronounced for saffron
1, 2 and 3 (J). Data are represented as mean ± SEM (n ≥ 3). p values were calculated using one-way
ANOVA, * p < 0.05.
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3.2. Saffron Reduces the Migration Rate of MACC1-Expressing CRC Cell Lines
To explore the effect of saffron crudes at the functional level, we assessed their impact on the
motility of different CRC cell lines. The migration reduction in high MACC1-expressing CRC cells
was observed after treatment with each of the saffron crudes. However, the reduction rates differed
among saffron samples. The highest decrease (61%) of the migration has been observed with saffron 3
in SW480/MACC1 compared to solvent-treated cells. Saffron 1, 2 and 4 decreased migration by 55%,
47% and 50%, respectively (Figure 2A). This observation was further substantiated in SW620 cells.
In the same direction, saffron 1, 2, 3, and 4 reduced migration of the SW620/Control cells by 46%,
42%, 33%, and 53%, respectively. None of the saffron crudes led to a significant migration decrease in
SW620/KO-MACC1 cells (Figure 2B).
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Figure 2. Saffron treatment reduced the migration of CRC cell lines. The low and high
MACC1-expressing cells were treated with saffron crudes, and their migration capacity has been
measured using the Boyden chamber ssay. The valu s were normalized to control cells treated with
solvent. Saffron crudes decreased the migratory capacity of the CRC cells in a MACC1-dependent
manner in both SW480 (A) and SW620 (B) cell lines. Data are represented as mean ± SEM (n ≥ 3).
p values were calculated using one-way ANOVA. * p < 0.05, ** p < 0.01.
3.3. Saffron Restricts Proliferation of CRC Cells with High MACC1 Expression through Cell Cycle Arrest
To test if reduced proliferation is due to cell death, we performed rescue experiments. To elucidate
if the effect of saffron on proliferation is reversible, we replaced saffron-containing medium after 24 h
with fresh saffron-free culture medium.
High MACC1-expressing cells pre-treated with saffron showed an enhanced proliferation rate
upon medium replacement (Figure 3A–D). This was most pronounced for saffron 3 (Figure 3C).
Unexpectedly, fresh medium replacement after saffron 2 treatment did not lead to a proliferation rate
enhancement (Figure 3B). To reveal how saffron leads to this effect cell cycle arrest was investigated.
Twenty-four hours of saffron 1, 2, 3, and 4 treatment increased the SW480/MACC1 cell portion
at G2/M phase up to 43%, 32%, 51%, and 40% compared to the solvent-treated cells, respectively.
More robust effects of the saffron treatment were observed in SW620 cell line. The cell fraction of
MACC1-expressing positive cells at G2/M phase increased under saffron 1, 2, 3, and 4 treatments up to
58%, 50%, 62%, and 55% compared to the untreated controls, respectively. This effect was reduced
in SW620/KO-MACC1 with no MACC1 expression. (Figure 3E–H). The MACC1 negative cell lines
(SW480/control and SW620/KO-MACC1) are still affected by saffron treatment, pointing to additional
MACC1-independent effects.
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Figure 3. Saffron treat ent led to cell cycle arrest upon MACC1 expression. Replacement of
saffron-medium with saffron-free medium after 24 h increased the proliferation of CRC cells with high
MACC1 expression. As a control, the cells were treated with freshly pre ff il tions after
24 h (A–D). In agreement with the rescue experiment, via PI staining the cell cycle distribution of the
cells was investigated. Twenty-four hour saffron exposure increased the cell portion at G2/M phase in
MACC1 overexpressing CRC cells (E–H). Forty-eight hours of saffron treatment did not increase the
cleaved-caspase 3 and cleaved-PARP level of the treated cancer cells compared to untreated controls (I).
In different studies, it has been suggested that saffron induces apoptosis [25]. Therefore,
we investigated cleaved-caspase-3 and PARP levels in CRC cells after saffron treatment. We did
not detect any changes in the protein level of cleaved-caspase-3 or PARP (Figure 3I) under any
saffron treatment.
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3.4. Crocin Is the Main Compound Responsible for MACC1-Dependent Anti-Proliferative Effect of Saffron
Major saffron compounds are crocetin, safranal and crocin [26]. It is not clear which compound
mediates the MACC1-dependent effects. Therefore, we investigated the effect of these major compounds
on CRC cell proliferation (Figure 4A–F). Crocetin treatment of CRC cells for 72 h did not lead to any
proliferation reduction regardless of the MACC1 expression level (Figure 4A,B). Safranal reduced the
proliferation of CRC cells independent of MACC1 level (Figure 4C,D).
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Figure 4. Crocin reproduced the MACC1-dependent effect of saffron. Cells were treated with different
crocetin concentrations. Crocetin did not reduce the proliferation of both MACC1 high and low
expressing cells (A,B). Safranal reduced the prolif ration rate of both cell lines in a MACC1-independent
manner (C,D). rocin decreased the proliferation rate of the CRC cells with high MACC1 level (E,F).
In addition, migration reduction in high MACC1-expressing CRC cells was observed under crocin
treatment in Boyden chamber assay (G). Following this, via chromatography analysis, the direct read
of crocin extract of each saffron was established. High variation of crocin has been observed between
the four different saffron extracts (H). Data are represented as mean ± SEM (n ≥ 3). p values were
calculated using Student’s t-test. * p < 0.05.
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However, crocin-treated SW480/MACC1 cells (high MACC1 expression) showed a 2-fold decreased
proliferation compared to control (Figure 4E). In the SW480/Control cells (low MACC1 expression),
the proliferation reduction was not observed upon crocin treatment. The same effect has been confirmed
in SW620 cells (Figure 4F). The SW620/Control cells (high MACC1 expression) showed a 2-fold lower
proliferation under crocin treatment compared to SW620/KO-MACC1 cells (no MACC1 expression)
(Figure 4F). In addition, crocin treatment led to the reduction of the migration rate of SW480 cells with
high MACC1 expression (Figure 4G).
In an independent liquid chromatography, the distribution of crocin in each saffron sample was
analyzed. We observed a high variability among the different saffron samples in the crocin levels.
While extracts of saffron 1 and 3 had the highest crocin amounts, saffron 2 and 4 showed lower amounts
(Figure 4H).
3.5. Saffron Reduces DCLK1 Levels in CRC Cells
Crocetin, a saffron compound, can reduce DCLK1 levels in vitro [23]. Therefore, we tested
the molecular connection of MACC1 and DCLK1. We overexpressed MACC1 and DCLK1 fused
to fluorescent markers in HEK293T cells. After pull-down of either protein, we found the other
one as interaction partner. This interaction was confirmed in a CRC cell line with ectopic MACC1
overexpression (Figure 5A). DCLK1 is a transmembrane protein, whereas MACC1 is mainly located in
the cytoplasm. Analyzing the location of DCLK1 and MACC1 in cells by FRET revealed that both
proteins are interacting at the membrane (Figure 5B). To prove the productive nature of the interaction
at the membrane, we used isolated recombinant proteins in a radioactive kinase assay. Incubating
DCLK1 with MACC1, we found a time-dependent transfer of 32P to MACC1. This shows that both
proteins are not only co-localized at the membrane, but that DCLK1 can phosphorylate MACC1
(Figure 5C).
DCLK1 has been discussed in several studies as a target for new therapeutic approaches in
CRC [27–29]. In respect to this, we investigated the effect of saffron and crocin treatments on the
DCLK1 expression levels. CRC cells with high MACC1 expression showed elevated levels of DCLK1
compared to the respective cell line with low MACC1 expression (Figure 6A, each control treated
cell pair). Treatments with saffron crudes or crocin for 48 h reduced DCLK1 protein levels in high
MACC1-expressing cells (Figure 6A).
Correlatively to this, we also studied the effect of the DCLK1 inhibitor, LRRK2-IN-1, which is an
ATP competitive substance, on the DCLK1 and MACC1 expression of these cells. The DCLK1 inhibitor
decreased the DCLK1 mRNA expression (Figure 6B). Additionally, MACC1 mRNA expression was
decreased at low inhibitor doses (Figure 6C). At elevated inhibitor doses starting at 3.13 µM it also led
to an induction of MACC1 mRNA expression in a concentration-dependent manner (Figure 6C).
Here we showed the ability of different natural saffron crudes and its crocin compound to inhibit
MACC1-induced proliferation and motility, thereby reducing CRC metastatic potential. Mechanistically,
we newly identified the interaction and direct phosphorylation of MACC1 by DCLK1, which is inhibited
by saffron through downregulation of DCLK1. Therefore, the MACC1-DCLK1 interaction could be
used as a therapeutic target for saffron extracts to inhibit metastasis formation mediated by MACC1.
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4. Discussion
CRC is one of the most common cancers and causes of morbidity and mortality in the world [2,30].
Despite therapeutic developments, the 5-year overall survival rate of patients with metastasis is still
low [31]. MACC1 is a metastasis driving gene, whose upregulation drops the 5-year metastasis-free
survival rate of CRC patients to 15% compared to 80% for patients with low MACC1 expression [6,8].
MACC1 is involved in the regulation of cell viability, proliferation and migration. This is mediated
through dysregulation of PI3K/AKT, MAPK/ERK and other pathways as reported by various research
groups for different tumor entities [6,32]. Therefore, it is crucial to intervene in the carcinogenic, tumor-
and metastasis-promoting effects of this oncogene. In the present study, we investigated the impact of
the natural product saffron on the tumor-promoting impact of MACC1. We showed for the first time
the concentration- and MACC1-dependent anti-proliferative and anti-migratory effects of saffron on
CRC cell lines via the downregulation of the CSC marker DCLK1 (Graphical abstract).
In our study, we have chosen saffron, one of the promising natural products, which has been used
for centuries to treat different diseases [33]. In recent years, the anti-tumor effects of this herb have
been investigated by a considerable number of different research groups in different tumor entities,
including lung, breast, and colon cancer [13]. These studies gave hints for the possible anti-metastatic
effects of saffron crudes and its compounds by downregulating metastasis-associated genes such as
MMP-2, -9 and Wnt pathway target genes including FZD7, NEDD9, VIM, and VEGF-α [19,34,35].
In the present study, we demonstrated that saffron crudes and its main compound crocin can be
used to supplement current treatments for CRC. Indeed, total crudes from different saffron samples
restricted proliferation of CRC cells with endogenous high MACC1 expression (SW620/Control) and
with forced overexpression of MACC1 (SW480/MACC1) in a dose-dependent manner. The strongest
effects were observed at the highest saffron extract concentration. When using lower saffron crude
concentrations, only minor or no effects were observed.
There is a considerable amount of studies indicating that the ratio of compounds provided by
saffron changes in different sources. Previous studies of different groups elucidated that the seed origin,
the planting conditions like soil type, altitude, climate, and harvesting time affect the compounds
composition of this herb [36–38]. Concordantly, in our study we observed that each of the saffron
crudes led to different reduction rates of cell proliferation and motility. This likely reflects different
compositions and concentrations of their active compounds. This is indeed the reason why typing
and cataloging of different samples is needed to maintain preventive and therapeutic characteristics
of saffron. In this work, the MACC1-dependent efficacy of saffron was analyzed in SW480 cells and
CRISPR-Cas9-mediated MACC1 knock-out clones of SW620, both with very low MACC1 expression
in comparison to MACC1-expressing counterparts. In both cell systems the saffron crudes did not
inhibit motility by SW620/KO-MACC1 and SW480/Control due to the missing target (MACC1).
Previous studies suggested that saffron can induce apoptosis and cell cycle arrest in different
tumor entities. Therefore, we further tested which pathway saffron affects when it downregulates
MACC1. Using PI staining, we established that the tested saffron crudes induced the cell portion at
the G2/M phase. In SW480/MACC1 cells, up to 45% of the cells were stalled in G2/M compared to
the solvent-treated cells. Stronger effects of the saffron treatment were observed in SW620/Control
cells with even higher MACC1 expression compared to SW480/MACC1. This result shows that saffron
increases the MACC1-expressing cell portion at G2/M-Phase. However, from this assay we cannot
entirely distinguish between cell cycle arrest and delay of cell cycle progression. The saffron effect
on cell cycle arrest was strongly reduced in the tested CRC cell lines with low MACC1 expression
(SW480/Control and SW620/KO-MACC1).
These findings establish that saffron primarily causes a MACC1-dependent cell cycle arrest.
Several studies have speculated that saffron might also act through induction of apoptosis [16,39,40].
This was not the case in the MACC1 system. Indeed, protein expression analysis showed that apoptosis
has remained the same with no increased caspase-3 levels after saffron exposure.
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We tested different major saffron compounds in the MACC1-expressing cell system. Exposure of
SW480/MACC1 and SW620/Control cells, both with high MACC1 expression, to various concentrations
of crocetin showed no proliferation inhibition. Safranal reduced the proliferation rate of the CRC cells
independent of the MACC1 level. This suggests a different mode of action of this compound. Indeed,
Amin et al. have reported that safranal induces an ER-stress-mediated cell death accompanied by DNA
double-strand breaks in hepatocellular carcinoma cells, but no cell cycle arrest [41]. Crocin was found
to be the main compound that could reproduce the effects of total saffron crudes in both cell lines with
MACC1 expression (SW480/MACC1 and SW620/Control) in a MACC1- and concentration-dependent
manner. We have shown that the MACC1-induced proliferation and migration are reversed due to a
delay/block in cell cycle progression at the G2/M phase. These results were further complemented by
an independent liquid chromatography. This analysis showed that saffron 3 contained the highest
crocin amount among the four saffron crudes used in our study. Saffron 3 led to the highest reduction
of proliferation and migration of high MACC1-expressing CRC cells.
Several studies assigned most of the observed anti-metastatic effects of saffron to its crocin content
in different types of cancers including breast, esophageal and melanoma [42–44]. Different molecular
mechanisms of action of crocin have been described in these systems. A review by Hoshyar et al.
summed up crocin´s inhibitory effects on cancer cell proliferation and induction of apoptosis through
various mechanisms [45]. Thus, the here identified direct connection to MACC1 is a novel mechanism
of crocin.
Rangarajan et al. suggested that saffron’s crocetinic acid can reduce DCLK1 levels in pancreatic
cancer [23]. We have shown here the interaction of MACC1 with the CSC marker DCLK1. Subsequently,
MACC1 gets phosphorylated by DCLK1. DCLK1 promotes tumor initiation and metastasis formation
in different tumor entities including breast, CRC, and pancreas [46–48]. It was first described as a kinase
important for motility of neurons during fetal brain development [49]. DCLK1 is a serine/threonine
kinase with association to the microtubule network, where it contributes to kinesin-3-dependent cargo
transport [50]. Its exact role and molecular functions are not fully understood. DCLK1 can act as an
intestinal CSC marker and is a potential target for novel therapies in CRC [51]. As for MACC1, DCLK1
increases in CRC during the transition from early-stage adenoma to more advanced dysplasia [52].
Mohammadi et al. have shown the regulation of DCLK1 by miR-200. Loss of the anti-cancer miR-200c
leads to an upregulation of DCLK1 and increased cellular motility [53]. This might be attributed to
the higher activation of MACC1 by DCLK1 in the MACC1-positive cell lines SW620/Control and
SW480/MACC1 used in this study. We have shown that saffron and crocin affect DCLK1 expression
levels. DCLK1 was also reported as a target for crocetinic acid when analyzing pancreatic cancer
in vitro and in vivo [23]. This saffron compound reduced the hedgehog signaling activity, affecting
pancreatic CSCs, resulting in inhibited pancreatic tumorigenesis [23]. This highlights the relevance of
DCLK1 as a major target in two different cancer entities (colon and pancreas), targeted by two different
compounds of saffron (crocin and crocetin).
Treatment with the DCLK1 inhibitor LRRK2-IN-1 first decreased the MACC1 mRNA expression at
lower inhibitor doses, but increased the MACC1 mRNA levels at higher doses. A possible explanation
for the MACC1 increase during DCLK1 inhibition could be related to the reduced availability of
phosphorylated, potentially activated MACC1. This might trigger the activation of MACC1 expression
to substitute the missing MACC1 activity.
The kinase DCLK1 is involved in stemness and in stem cell niche formation [54]. DCLK1 is
involved in numerous processes like proliferation, cell survival, drug resistance, angiogenesis, EMT,
invasion, and metastasis [48,55–59]. All these cellular features are mediated by MACC1 too [32]. How
the saffron crudes and crocin exert their effects on MACC1-dependent proliferation and migration is
not known. However, it was already described that saffron can inhibit DCLK1 gene expression [22]. We
identified and validated the interaction of MACC1 and DCLK1. This is, at least in part, a mechanistic
basis for the cancer and metastasis inhibitory effect of saffron.
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Taken together, the findings of this study reveal the MACC1-dependent anti-proliferative and
anti-migration effects of saffron on CRC cell lines. In conclusion, for MACC1-driven cells, the
anti-migration effect of saffron is strongly mediated by crocin. This is paralleled by a decrease in
proliferation and migration via reversible G2/M cell arrest. In summary, saffron is a promising herb for
the treatment of MACC1-expressing CRC. In addition, saffron might complement current standard
therapy modalities like radio- and chemotherapy. The application of saffron or its main compound
crocin for treatment of MACC1-driven CRC warrants further investigation.
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